Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Blood and Lymphatic Cancer: Targets and Therapy · 2017
DOI: 10.2147/blctt.s130197 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2017. Verfasst von Theodora Anagnostou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Rochester, Rochester, MN, USA, Litzow.Mark@mayo.edu. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Mayo Clinic Rochester, Rochester, MN, USA, Litzow.Mark@mayo.edu.
Zitieren
APA
Anagnostou, T., & Litzow, M. R. (2017). Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s130197
Vancouver
Anagnostou T, Litzow MR. Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives. Blood and Lymphatic Cancer: Targets and Therapy. 2017. doi:10.2147/blctt.s130197
BibTeX
@article{Anagnostou2017,
author = {Anagnostou, Theodora and Litzow, Mark R},
title = {Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2017},
doi = {10.2147/blctt.s130197}
}
EUVIMED